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Tumor dormancy and surgery-driven interruption 
of dormancy in breast cancer: learning from failures
Romano Demicheli*, Michael W Retsky, William JM Hrushesky and Michael Baum 
IntroductIon
A fundamental lesson of scientific thinking is 
the concept that science develops mostly from 
failures. The conceptual tools (that is, models or 
‘paradigms’) that are used to understand reality 
eventually demonstrate their inability to depict a 
reliable picture—in other words, they fail. We are 
then forced to implement new paradigms that can 
be used until they in turn fail, and so on. Such a 
process is tangible in oncology research, in which 
conceptual failures result in therapeutic failures, 
which ultimately result in disease recurrence and 
the death of patients.
In this Review, we analyze the evolution of two 
paradigms failing to explain the development of 
breast cancer metastases. As described herein, the 
assumption that metastases display continuous 
growth from inception is not reflected in clinical 
data. The observed and expected findings show 
a much better correlation when an interrupted 
tumor growth model is assumed, and this implies 
episodes of ‘tumor dormancy’. Moreover, the 
traditional concept that primary tumor removal 
is intrinsically beneficial should be viewed with 
caution. Indeed, experimental and clinical find-
ings indicate that excision of the tumor can 
perturb metastatic homeostasis and for some 
patients results in the acceleration of metastatic 
cancer. Taking into consideration the paradigms 
of tumor dormancy and the effects of surgery, a 
new model is developed that is not completely 
satisfactory and includes unresolved questions 
that will require further investigation. Within 
the scientific method, however, it is virtually 
impossible to prove a given model. Models can 
be disproved only when they result in substantial 
departure from observed findings. Until that time, 
we are justified in using them.
contInuouS GroWtH VErSuS tuMor 
dorMAncY
Growth models
The early exponential growth model proved to 
be adequate only for standard in vitro studies, 
while a satisfactory growth description in vivo 
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rEVIEW crItErIA
This Review includes a summary of the authors’ work over the past two decades 
as well as a series of specific reviews related to different topics involved in the 
research line. Data were obtained from the author’s own work, from continuous 
reading of the oncology literature during the past 20 years, and by searching 
the PubMed database. There was no restriction as to publication date for the 
papers searched on PubMed. The search terms used included “angiogenesis”, 
“dormancy”, “hormone receptor”, “growth model”, “menopausal status”, 
“metastasis” and “recurrence”.
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called for mathematical functions that reflect 
growth-retarding features. Among these, the 
Gompertzian function1 was generally consid-
ered adequate to describe neoplastic growth in 
the range of measurable tumors. When extra-
polated to a very early growth phase, however, 
the Gompertzian model does not have an initial 
exponential region of sufficient duration and 
usually has an implausibly short initial doubling 
time.2 More-complex models were, therefore, 
proposed to partially overcome these draw-
backs.3 In spite of their partial inadequacy, early 
growth models rendered remarkable services to 
oncology. The development of adjuvant systemic 
treatments was based on the exponential model4 
and refined by models based on Gompertzian 
growth kinetics.5 It should be emphasized that 
all these models assume the implicit hypothesis 
that tumors must always grow. They are ‘contin-
uous growth’ models. According to a continuous- 
growth model, the metastasis development 
following primary tumor removal can be illus-
trated as shown in Figure 1A. Recurrences with 
different disease-free survival (DFS) times result 
either from tumor foci with different sizes and 
similar growth rates (R1 and R2) or from foci 
with the same initial size and different growth 
rates (R2, R3 and R4). The diagnosis of recur-
rence is usually recognized some time after the 
metastasis size has exceeded the clinical threshold 
and, according to the continuous-growth model, 
the longer the DFS, the longer this time period 
(Figure 1, double-headed arrows).
Local recurrences
In patients who are regularly followed up, the 
detection of local recurrences is preceded by a 
series of physical examinations during which 
no tumor is detected (i.e. the patient is clini-
cally negative). This all-or-none phenomenon 
was chosen to test continuous-growth kinetics 
in a series of 120 breast cancer patients at the 
National Cancer Institute of Milan, who under-
went mastectomy without postoperative irradia-
tion and for whom the primary tumor site was 
also the site of first disease relapse (local recur-
rence).6 According to the hypothesis of contin-
uous growth, in each patient the diameter of 
the recurring tumor was measured, and the dia-
meter that the tumor would have reached at the 
immediately preceding negative physical exami-
nation was also calculated. The study proved that 
the continuous-growth model yielded tumor 
sizes significantly too large to have been missed 
at the previous physical examination, and the 
growth rates were significantly lower than those 
consistent with clinical data, which were notably 
similar among themselves. Moreover, it was 
noticed that discrepancies between expected and 
observed results were resolved, at least in part, 
by assuming that growth interruption or ‘tumor 
dormancy’ had occurred.
On the basis of these findings, the concept of 
uninterrupted (constant or retarded) growth 
of locally recurring tumors was rejected and the 
concept of tumor dormancy was assumed as a 
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Figure 1 Size versus time chart of metastasis development. (A) Metastasis 
development during the subclinical phase according to a continuous-growth 
model. Recurrences with different disease-free survival (DFS) times can 
result from tumor foci of different sizes at the time of primary tumor removal 
with similar growth rates (R1 and R2) or from foci of the same initial size with 
different growth rates (R2, R3 and R4). The clinical diagnosis is performed 
some time after the metastasis size exceeds the clinical threshold (double-
headed arrows) and, according to the principles of continuous growth, the 
longer the DFS, the longer this time period. (B) Metastasis development 
during the subclinical phase according to the tumor dormancy hypothesis. 
All recurrences have similar growth rates, and recurrences with different DFS 
times result from tumor foci of different sizes at the time of primary tumor 
removal (R1 and R2) or foci of the same initial size with different dormancy 
times (R2, R3 and R4).
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working hypothesis. According to this assump-
tion, the picture of metastasis development during 
the subclinical phase is changed (Figure 1B): the 
same DFS times (R2, R3, R4) as in Figure 1A 
will result from different tumor dormancy times 
followed by similar growth times.
treatment failures
A further investigation of the time distribution of 
treatment failures, which was studied utilizing the 
cause-specific hazard function for locoregional 
and/or distant recurrence as first event, was 
performed in 1,173 patients undergoing mastec-
tomy as primary treatment for operable breast 
cancer.7 The results of this study confirmed the 
inadequacy of the continuous-growth models. 
The recurrence pattern showed an early, fairly 
broad peak at about 18 months after surgery, 
followed by a second peak at about 60 months 
and then a tapered plateau-like tail extending 
up to 15 years (Figure 2A). Over half of all 
relapses occurred during the early peak. A more 
detailed analysis for recurrences of the first peak 
revealed a sharp two-peaked hazard function for 
premenopausal patients (Figure 2B), whereas the 
recurrence growth pattern in postmenopausal 
patients displayed a wide peak that was almost 
symmetrical in shape (Figure 2C).8
The second peak of the recurrence rate at 
about 60 months is not so well established as 
the first peak, and might be the result of a statis-
tical fluctuation. The best argument against this 
interpretation comes from the fact that this peak 
has been confirmed in other databases9–13 (even 
for mortality data and for patients receiving 
adjuvant chemotherapy) and might also be 
identifiable in other reports.14–21 The compara-
tive examination of different databases provides 
evidence that recurrence-risk peaks have rather 
similar timing for different patient subsets, thus 
suggesting that the disease course following 
surgical removal of the primary tumor basi-
cally follows a common pathway. Moreover, the 
finding that the risk level for the studied events 
at a certain time is influenced by tumor and host 
traits (e.g. the first peak is much less pronounced 
in series in which the prognosis is better) indi-
cates that the pace of the common pathway is 
governed by pre-existing risk factors likely to 
result in converging hazards, which display a 
common resonance.
The multipeaked nature of the recurrence 
and mortality patterns strongly suggests that 
the process of overt clinical metastases has 
discontinuous features that could not easily 
be explained by uninterrupted tumor growth 
since tumor seeding. The tumor dormancy 
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Figure 2 Hazard rate for recurrence of breast cancer in patients undergoing 
mastectomy (Milan series). (A) Hazard rate for tumor recurrence compiled from 
the data from 1,173 premenopausal and postmenopausal breast cancer patients 
undergoing mastectomy alone. The black squares relate to 3-month hazard rate 
values (with the corresponding standard deviations). The smoothed curve was 
obtained by a kernel-like smoothing procedure. (B,C) Detailed analysis of the first 
peak of recurrence risk (first 4 years following mastectomy) for premenopausal 
(B) and postmenopausal (C) patients. The black squares relate to 3-month hazard 
rate values (with the corresponding standard deviations). The smoothed curve 
was obtained by a kernel-like smoothing procedure.
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concept explains these findings well. Indeed, it 
could be assumed that at the time of primary 
tumor removal micrometastatic foci might be 
in different biological steady states, most of 
which are dormancy states, which might switch 
to growth states after certain mean times and 
produce the discreteness of the hazard pattern 
that is observed. Moreover, differences in the 
recurrence-risk pattern that are related to 
menopausal status are in keeping with an abun-
dance of findings about the age distribution of 
prognostic factors.22,23
tuMor dorMAncY And MEtAStASIS 
dEVELopMEnt
The occurrence of no growth of otherwise viable 
tumor foci is not a new concept.24 Dormant tumor 
cells were observed in several experimental 
models involving animal tumors,25–28 as well 
as in cell lines derived from human tumors.29,30 
Dormant, viable single cells have been identi-
fied in animal models,31–33 and small dormant 
micrometastases and larger growing micro-
metastases have also been observed in human 
breast cancer.34
There have been reports of dormant avascular 
micrometastases for which, in animal models, 
the no-growth status is maintained by a balance 
between proliferation and apoptosis.35 It has also 
been observed that angiogenic cells developed 
into early palpable tumors, whereas nonangio-
genic cells developed into palpable tumors after 
much longer mean times (dependent on tumor 
type), during which they remained microscopic 
in size with absent or nonfunctional vascula-
ture.36 These results indicate that the onset and 
extent of angiogenesis are critical determinants 
of tumor progression and growth.
A molecular mechanism for tumor dormancy 
of single cells has been identified.37 The tumori-
genic cells express high levels of the urokinase-
type plasminogen activator–urokinase-type 
plasminogen activator/receptor (uPA–uPAR) 
complex, which, by interacting with and acti-
vating fibronectin-bound α5β1 integrin, initiates a 
signaling pathway through focal adhesion kinase 
(FAK), EGFR and extracellular signal-regulated 
kinase (ERK), leading to a high ERK-to-p38 ratio 
and rapid tumor growth in vivo. Inactivation of 
the uPAR–α5β1 complex reverses the ERK-to-p38 
ratio, favoring p38 activation and forcing these 
cells into growth arrest and dormancy in vivo.37 
This mechanism is particularly appealing as it 
proved to be modulated by extracellular signals 
in vivo and is consistent with a prominent role 
of the tumor cell and microenvironment inter-
actions. It might reasonably be assumed that the 
repertoire of cancer-cell-surface proteins is crucial 
for the ability of tumor cells to receive, transmit 
and interpret clues from growth-permissive or 
growth-nonpermissive microenvironments, and 
to initiate signaling programs that respectively 
favor growth or dormancy.
Tumor growth and the development of the 
metastatic process can be represented schemati-
cally (Figure 3A). Tumor cells leave the primary 
site as single cells and seed at a distant site or tissue 
where they may lodge for some time in a quies-
cent state.28,32,33,38,39 This first dormant state, 
denoted S1, lasts until tumor-cell or seeded-tissue 
changes induce cell proliferation. The transition 
from resting to growing tumor is likely to have 
prominent stochastic features.40,41 The growing 
phase following S1 might lead to different fates 
depending on the ability to induce angiogenesis. 
Indeed, only a subset (4–10%) of primary 
tumor cells and presumably a subset of meta-
static cells have the angiogenic phenotype.35,42 
Angiogenic micrometastases in the presence of 
antiangiogenic factors and nonangiogenic micro-
metastases, therefore, cannot expand to more than 
the size of avascular foci, containing a range of 
2 × 103 to 1.5 × 105 cells.31,42,43 Micrometastases 
can escape the second dormant state (S2) by 
at least two mechanisms. For instance, the 
removal of an angiogenesis inhibitor might 
release those cells already capable of inducing 
neovascularization, or a subset of tumor cells 
within the micrometastases might switch to an 
angiogenic phenotype.35,36
In the described model, proposed for breast 
cancer44 as well as for other cancers,45 meta-
static tumors can either grow continuously or 
sojourn in the two dormant states S1 and S2. 
Orderly transitions between these two dormant 
states eventually result in progressive appear-
ance of clinical metastases. In a computer simu-
lation of this model, however, development of 
the early peak was detectable only by assuming 
some precipitating event at or near the time of 
surgery.46 Even a simple examination of the 
recurrence-risk pattern (see Figure 2) suggests 
the occurrence of a triggering event that causes 
recurrence synchronization. After excluding 
some possible non-biology-based explanations 
of this finding,8 we can hypothesize that surgical 
removal of the primary tumor may in itself have 
this triggering effect.
© 2007 Nature Publishing Group 
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prIMArY tuMor rEMoVAL  
And MEtAStASIS dEVELopMEnt
primary tumor removal in animal models
The presence of ‘outbursts’ of metastatic growth 
following surgical excision of the primary tumor 
is a well-recognized phenomenon in both the 
experimental and the clinical setting.47,48 
A biphasic effect of surgery on lifespan was 
observed: very early surgery in the Lewis lung 
tumor model in mice resulted in a few long-term 
survivors, while delayed surgery had a detri-
mental effect on lifespan.49 In rodents, partial 
or total tumor removal resulted in stimulation 
of cell proliferation in macrometastatic foci 
via a growth-stimulating factor.49–53 Effective 
systemic treatment given before or immediately 
after surgery completely suppressed the prolif-
eration increase and delayed metastasis growth 
in murine mammary tumor studies.54
Investigations have started to elucidate the 
mechanisms by which primary tumor removal 
might accelerate the metastatic process. Single 
cells might be induced to proliferate via the 
conversion of noncycling G0 cells,53,55 and 
dormant avascular micrometastatic foci could 
be switched to active angiogenesis by shifting 
the balance between positive and negative 
angiogenic factors.36,43,56 Alternatively, changes 
in the steady-state dynamics resulting from the 
switching of a subset of tumor cells to angio-
genic phenotype might also occur.35 Surgical 
wounding in itself might also be involved. In 
animal models, proliferation enhancement of 
metastatic foci following surgical trauma has 
been observed,52,57 and in animals and humans, 
wound-derived factors stimulating angiogenesis 
and proliferation have been recovered.58,59 All 
these findings support the concept that the pres-
ence of the primary tumor might exert some kind 
of homeostatic effect upon distant metastases by 
mechanisms, which are not yet well elucidated, 
that result in inhibited proliferation and/or 
enhanced apoptosis. A hypothesized presurgical 
condition is illustrated in Figure 3B.
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Figure 3 Outline of the metastatic process of breast cancer. (A) Tumor cells leave the primary tumor (T) 
as single cells and seed the distant tissue, where they may lodge for some time in a quiescent state (S1) 
or go on proliferating. Quiescent cells can be induced to proliferate by intrinsic or microenvironmental 
changes. Growth following S1: nonangiogenic micrometastases (and angiogenic micrometastases in the 
presence of antiangiogenic factors) cannot grow to more than the size of avascular foci (S2). A further 
growth phase implies the absence or removal of angiogenesis inhibitors in order to release those already 
capable of inducing neovascularization, or else the switch to an angiogenic phenotype of a subset of 
tumor cells within hitherto nonangiogenic micrometastases. Only after the start of the vascular phase 
may micrometastases grow until overt clinical recurrence ensues (M). (B) It may be hypothesized that the 
presence of the primary tumor exerts some kind of homeostatic effect upon distant metastases, resulting 
in inhibited proliferation and/or enhanced apoptosis. In the presurgical condition the primary tumor 
somewhat restrains S1→S2 and S2→M transitions, causing the dormancy of single cells and avascular 
micrometastases. Primary tumor removal might concur to enhance transitions and then to fuel the 
metastatic process.
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primary tumor removal and disease 
outcome in patients with breast cancer
Clues as to how primary tumor removal can affect 
breast cancer outcome have been reported.60 
The hazard rates for death of patients who did 
not receive any form of effective treatment were 
calculated from the database reported by Bloom 
and coauthors61 and were compared with the 
above-mentioned series (‘Milan series’)6 of 
patients undergoing mastectomy alone (Figure 4). 
The hazard curves showed an increase in the risk 
of death followed by a near-constant plateau for 
the untreated patients and a double-peaked 
pattern (with hazard rate values clearly lower) for 
patients undergoing mastectomy. The different 
patterns of death risk can be attributed to the 
multiple consequence of mastectomy: the ‘cure’ 
of a considerable fraction of patients (shown 
by the lowering of hazard rates), and the change 
in the natural timings of recurrence and death 
for other patient subsets (shown by the different 
hazard rate curves).
Further persuasive arguments for an effect of 
primary tumor removal on outcome are provided 
by the congruence between the recurrence- 
risk pattern (Figure 2A) and the putative surgery-
related changes in the metastatic process. Indeed, 
removal of the primary tumor will result in 
sudden release of its restraints on the metastatic 
process (Figure 3B), with a marked increase in 
the transition rate between S1 and S2 by stimu-
lated proliferation of a number of single cells 
(the ‘Fisher effect’),53 and between the S2 and 
M phases by induced angiogenesis in some 
micrometastases (the ‘Folkman effect’).35
It can be assumed that the early sharp peak in 
hazard rate observed for premenopausal patients 
(Figure 5) can be ascribed to development of 
angiogenic activity in a considerable number 
of previously avascular micrometastases. The 
sharpness of this peak supports the supposition 
that a triggering event occurs. The position of 
the peak, implying rapid activation and tumor 
growth within 8–10 months, is in quite good 
agreement with estimates of tumor growth 
following dormancy release (30 ± 8 weeks or 
less) obtained by very different methodology.62 
The subsequent broader peak at 28–30 months 
could result from the Fisher effect, resulting in 
the development of successive avascular micro-
metastases, followed by ‘spontaneous’ switching 
to the angiogenic phenotype after a certain 
period in the S2 phase. For postmenopausal 
patients, for whom the first sharp peak is absent 
and the single broad peak is at 18–20 months, it 
should be assumed that surgery-driven acceler-
ating effects are much more modest (Figure 6). 
Furthermore, the model’s assumptions suggest 
that the rather poor prognosis after the diag-
nosis of local recurrence might be related to the 
surgery undertaken for tumor control rather 
than having to postulate ‘tertiary’ spread of 
the disease.
According to the tumor dormancy model, 
factors related to menopausal status control 
the effects of surgical treatment. There is strong 
evidence to support the idea that recurrence of 
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Figure 4 Hazard rate for death of breast cancer patients: comparison between 
untreated patients and patients undergoing mastectomy. (A) Death-specific 
hazard rate for 250 patients from the historical database of Bloom et al., who 
did not receive any form of surgery, radiation therapy or hormone therapy. 
The circles represent yearly hazard rate values (with the corresponding 
standard deviations). The smoothed curve shows a single death risk surge 
followed by a near-constant plateau. (B) Death-specific hazard rate for 1,173 
patients undergoing mastectomy alone (‘Milan Series’). The circles represent 
yearly hazard rate values (with the corresponding standard deviations). The 
smoothed curve shows a double-peaked pattern with hazard rate values 
clearly lower than the corresponding values of the Bloom series (note the 
different units on the hazard rate axis). Permission obtained from Nature 
Publishing Group © Demicheli R et al. (2001) Br J Cancer 85: 490–492.
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metastatic disease following resection depends 
to some extent upon the sex-hormone milieu at 
the time of breast cancer resection. It has been 
reported that the risk of postresection cancer 
spread is two to four times greater among 
women in the follicular phase of their menstrual 
cycle at the time of resection than among women 
undergoing surgery in the early luteal phase of 
their menstrual cycle.63 Furthermore, this post-
resection cancer spread is mediated by estrogen-
induced control of tumor cell VEGF content and 
capillary permeability.64
outcome following adjuvant chemotherapy
Confirmation of the main features of the meta-
stasis development model outlined above 
came from analysis of the recurrence risk for 
patients receiving adjuvant cyclophosphamide, 
methotrexate and fluorouracil (CMF).13,65 The 
analysis demonstrated that nearly all benefit of 
CMF treatment occurs during the first 4 years 
following resection and chemotherapy, and that 
the reductions in recurrence occur in specific, 
temporally separate recurrence clusters in the 
first and third years, for both menopausal statuses 
(Figure 7A,B). These findings suggest that the 
recurrence pattern following mastectomy might 
result from the superimposition of three meta-
static clusters peaking at about 7–10 months, 
17–20 months and 27–33 months, respectively 
(Figure 7C,D). The first and the third clusters 
are chemosensitive and are nearly obliterated by 
adjuvant CMF, while the intermediate cluster is 
relatively refractory to the administered treat-
ment. The cluster sizes in premenopausal and 
in postmenopausal patients are quite different. 
Young premenopausal women display promi-
nent peaks of chemosensitive recurrences in 
the first and third years, which mask the second 
peak; by contrast, these two peaks are obscured 
by the dominance of the intermediate one in 
older patients.
These results are expected if the model 
assumptions are that following surgical removal 
of the primary tumor, two highly proliferative, 
surgery-driven processes are under way. In 
response to effective cytotoxic chemotherapy 
that targets proliferating cells, reductions in 
recurrence rates would be expected to occur 
at different times, as in fact occurs. The model 
assumes, moreover, that during treatment 
administration other metastases, such as those 
not engaged into transition processes between 
dormant states, display minor proliferative 
activity and there might be metastases that are 
nonresponsive (for single cells)66,67 or mildly 
responsive (for avascular micrometastases) to 
cytotoxic drugs, thus escaping important treat-
ment effects. The second-year recurrences that 
are poorly affected by adjuvant therapy could 
arise by this mechanism.
The conclusions from this analysis of clin-
ical findings yield evidence that the metastatic 
process is similar for both menopausal statuses, 
although both Fisher and Folkman effects 
might be larger in younger women. Therefore, 
the model provides biological reasons for why 
adjuvant chemotherapy is especially effective in 
premenopausal patients.68
Menopause-related sensitivity to surgery
The proposed model suggests that premeno-
pausal and postmenopausal patients might have 
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Figure 5 Outline of the hypothesized dynamics of metastasis development 
in premenopausal patients with breast cancer. Removal of the primary tumor 
(time = 0) results in a sudden increase in the rate of transition from S1 to S2 (by 
stimulated proliferation of a number of single cells) and from S2 to M (by the 
induction of angiogenesis in avascular micrometastases). In a considerable 
fraction of premenopausal patients, a number of S2 micrometastases are capable 
of giving rise to neovascularization, but are restrained by the primary tumor; 
therefore, they switch to angiogenic activity after the tumor is removed, and will 
reach clinical size (M) in about 8–10 months (1st peak). Single cells from S1 start 
proliferating and quickly generate micrometastases that are mostly avascular and 
not growing, since apoptotic activity balances proliferative activity (solid circular 
arrow). These micrometastases may resume growing after spontaneous switching 
to the angiogenic phenotype, a process with a more protracted mean time. They 
will reach clinical size only after 28–30 months (2nd peak). The surgery-driven 
acceleration of the metastatic process, resulting in the two hazard rate peaks, 
exceeds the ‘regular’ transition from S2 to M, the contribution of which arises at 
an intermediate time (dashed circular arrow and arrow). Hazard rate versus time 
diagram: the two peaks are followed by the 60-month peak. 
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differing sensitivities to the accelerating effect 
of surgery. This hypothesis is quite reasonable. 
Although there is strong evidence that cumu-
lative exposure to estrogens and progesterone 
has significant influence on the risk of breast 
cancer,69 some reproductive events (puberty, 
pregnancy, lactation, weaning and menopause) 
affect the level of risk in different ways according 
to the age at diagnosis of breast cancer.70 For 
example, histological grade and hormone 
receptor levels proved to have different age distri-
butions and age-specific incidence rate patterns, 
with typical changes seen at menopause.71 Even 
short-term changes of the host physiological 
conditions, such as those of the hormone milieu 
during the menstrual cycle, can result in measur-
able differences in some biological variables of 
breast cancer.72,73 Indeed, levels of sex hormones 
that modulate angiogenesis in the normal female 
reproductive system, mainly via effects on endo-
thelial cells,74 also participate in the regulation 
of angiogenesis in breast tissue.
VEGF levels in normal breast tissue vary 
within each menstrual cycle.75 Estrogens have 
been shown to regulate the bioactive frac-
tion of VEGF in normal human breast tissue 
in vivo,76 and to drive proangiogenic effects in 
animal models,77 while tamoxifen caused anti-
angiogenic effects.78 Plasma levels of endostatin, 
a negative regulator of angiogenesis, are signifi-
cantly higher in postmenopausal patients than in 
premenopausal ones79 Furthermore, differences 
relating to angiogenesis have been observed 
between tumors of premenopausal patients and 
those of postmenopausal patients.80,81
Other findings also support the fact that 
tumor cells have subtle and rapid sensitivity 
to environmental factors. The circadian clock 
within cancer cells apparently coordinates the 
cancer growth rate.82 The mechanisms of inter-
mittent cancer growth include circadian clock 
coordination of VEGF-induced capillary perme-
ability and blood flow.83 As with the circadian 
cycle, cancer growth rate and postresection 
metastatic potential are each regulated by the 
mammalian reproductive cycle. The estrogen:
progesterone ratio apparently regulates cancer-
cell VEGF and basic fibroblast growth factor, 
and cancer growth rate and metastatic poten-
tial.64,84 To conclude, it is reasonable to assume 
that some conditions related to menopausal 
status may favor neoplastic cell populations with 
peculiar traits relative to angiogenesis.
concLuSIonS And FuturE 
dEVELopMEntS
Several issues remain to be addressed, as the 
interrupted-growth model clarifies some 
clinical observations whilst at the same time 
posing new questions. Regarding new treatment 
options, the model suggests both the usefulness 
of therapy with angiogenesis inhibitors85 and of 
metronomic therapy (i.e. the steady schedule 
of comparatively low doses of certain cytotoxic 
agents targeting tumor-associated endothelial 
cells),86 and the need to be watchful for possible 
interference with standard chemotherapy.
Starting from CMF, adjuvant chemotherapy 
has expanded into more-effective combinations 
with the introduction of anthracyclines, taxanes 
and trastuzumab. Adjuvant hormone therapy, 
such as with tamoxifen or aromatase inhibitors, 
is currently adopted in many clinical settings. 
It is not known how the recurrence dynamics 
change following application of these new adju-
vant treatments. Mastectomy has been replaced 
by conservative surgery in most clinical condi-
tions. The effect of the new surgical approach 
should be investigated, as the extent of damage 
induced by surgery may modulate the intensity 
of the proliferative stimulus.59
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Figure 6 Outline of the hypothesized dynamics of metastasis development 
in postmenopausal patients with breast cancer. The processes described are 
similar to those for premenopausal women. For postmenopausal patients the 
surgery-driven acceleration of the metastatic process is moderate, the ‘regular’ 
transition from S2 to M predominates, and its contribution to the hazard rate 
curve hides both the early and the late peak. Hazard rate versus time diagram: 
the single peak is followed by the 60-month peak.
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Primary preoperative chemotherapy has a 
varying and assessable effect on the primary tumor 
before surgery, and presumably it influences even 
micrometastases. It is likely that the recurrence 
dynamics will be affected, and careful analysis of 
these dynamics will provide new elements that 
will help to further clarify the process of metastasis 
development. Finally, as a primary tumor seems to 
be able to control the fate of its own metastases, 
what specific information is carried that keeps 
them in this quiescent state? What factors govern 
the initiation of metastasis in the early multipeak 
phases, when tumor traits probably dominate, and 
during the late plateau, when host factors might be 
more prominent? Answers to these questions are 
crucial as most, if not all, breast cancer patients 
are likely to harbor dormant neoplastic cells for 
the rest of their lives.87
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Figure 7 Pattern of CMF-sensitive and CMF-refractory recurrences occurring in the first 4 years following mastectomy. (A,B) Hazard 
rate for recurrence during the first 4 years following mastectomy for premenopausal patients (A) and postmenopausal patients (B):  
6 cycles of CMF versus 12 cycles of CMF versus no adjuvant treatment. For both menopausal statuses, the recurrence reduction 
occurs at specific, temporally separate recurrence clusters at the first and third years. (C,d) The total recurrence pattern of untreated 
patients (purple) may be broken up into three metastatic clusters peaking at about 7–10 months, 17–20 months and 27–33 months. 
The first and third clusters are chemosensitive and are nearly obliterated by adjuvant CMF, while the intermediate cluster is relatively 
refractory to the administered treatment. At the first and third years, young (premenopausal) women (C) display prominent peaks of 
chemosensitive recurrences which hide the second (intermediate) peak, whereas for older patients (D) these two peaks are obscured 
by the dominance of the intermediate one. Abbreviation: CMF, cyclophosphamide, methotrexate and fluorouracil. Permission obtained 
from Oxford University Press © Demicheli R et al. (2005) Breast cancer recurrence dynamics following adjuvant CMF is consistent with 
tumour dormancy and mastectomy-driven acceleration of the metastatic process. Ann Oncol 16: 1449–1457.
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KEY poIntS
■ Established tumor growth models that 
assume continuous growth of a tumor fail to 
explain clinical findings from breast cancer 
patients with local or distant recurrence; such 
discrepancies may be explained by tumor 
dormancy
■ The hazard rate for tumor recurrence soon 
after surgery displays a pattern that is related 
to menopausal status: a two-peaked hazard 
function for premenopausal patients and a 
single wider peak for postmenopausal patients
■ It has been confirmed that in patients receiving 
adjuvant chemotherapy, recurrence risk is 
reduced at the first and third years for both 
menopausal statuses
■ Subclinical metastases might be induced to 
grow by the conversion of single noncycling 
G0 cells or by the switching of avascular 
micrometastatic foci to active angiogenesis
■ Assuming a triggering effect of surgical 
removal of the primary tumor, the early sharp 
recurrence peak seen in premenopausal 
patients can be ascribed to the switching 
of micrometastatic foci to the angiogenic 
phenotype, while the following broader peak 
might result from interruption of dormancy of a 
number of single cells
■ For postmenopausal patients, the accelerating 
effects of surgery are much more modest
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